

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	9355704
<b>Application Number:</b>	10591628
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	1403
<b>Title of Invention:</b>	Granulocyte Subtype-Selective Receptors And Ion Channels And Uses Thereof
<b>First Named Inventor/Applicant Name:</b>	Chaker N. Adra
<b>Customer Number:</b>	23628
<b>Filer:</b>	Roque El-Hayek/Paula Bramwell
<b>Filer Authorized By:</b>	Roque El-Hayek
<b>Attorney Docket Number:</b>	A0852.70000US01
<b>Receipt Date:</b>	01-FEB-2011
<b>Filing Date:</b>	16-NOV-2007
<b>Time Stamp:</b>	17:00:13
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$735
RAM confirmation Number	3659
Deposit Account	232825
Authorized User	EL-HAYEK,ROQUE

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:  
Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	A085270000US01-TRN-RE.pdf	48802	no	1
			f47751ab00a6743699227790231f4853c846e89c		
Warnings:					
Information:					
2	Extension of Time	A085270000US01-EXT-RE.pdf	55084	no	1
			34729a2bb5516ed9353f50a0e6fa3332a8935971		
Warnings:					
Information:					
3	Fee Worksheet (PTO-875)	A085270000US01-FEE-RE.pdf	68592	no	1
			9e738c1869dc73079bf65032fb9c36b484b1d422		
Warnings:					
Information:					
4		A085270000US01-AMN-RE.pdf	491433	yes	11
			69f767887a0d69af1b215f7ed62d8a8757aa9d46		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment/Req. Reconsideration-After Non-Final Reject		1	1	
	Specification		2	3	
	Claims		4	7	
	Applicant Arguments/Remarks Made in an Amendment		8	11	
Warnings:					
Information:					
5		A085270000US01-IDS-RE.pdf	262083	yes	5
			6c2240d9af30c437ba9bf21d960b5d35336a0a3d		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Transmittal Letter		1	3	
	Information Disclosure Statement (IDS) Filed (SB/08)		4	5	
Warnings:					

<b>Information:</b>					
6	NPL Documents	A085270000WO00_IPRP.pdf	393116 a51dd0cc608795ead14fe19fc6d9177fa35919d	no	9
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	A085270000WO00_ISR.pdf	771219 8ecd486723cc07dc699f5f36769fb8bfbcab15d0	no	16
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	Adra_et_al_PNAS_1994_v91_p10178.pdf	1547268 8b6d19ac5311da94ac12b44b5618312148e3f611	no	5
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	Arock_et_al_JLeukocytBiol_2002_v71_p557.pdf	329127 22d06c2e45e882cc39693420d2ef0910c320d40e	no	8
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	Bennett_et_al_J_Exp_Med_2003_v197_p711.pdf	25617886 4edb4a8977e9cc8c7c67408cb9a2bba5b6d648b4	no	13
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	Berliner_et_al_Blood_1995_v85_p799.pdf	6586042 2ff563dc36461aedad6c3e9693493574e94dd74e	no	5
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	Bradding_et_al_JLeukocytBiol_2003_v73_p614.pdf	92365 7948869daae4ea01842c278697e4135e7f8f68fc7	no	7
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	Floyd_et_al_J_Biolog_Chem_2000_v275_p861.pdf	514585 dbfccc3b3cf47790f93483c540c2666b4bee1168	no	6
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	lida_et_al_Blood_2001_v97_p1016.pdf	137938 4f397c9053f415c742e5f131a642163fc420520	no	7
<b>Warnings:</b>					

Information:					
15	NPL Documents	Loitta_et_al_JLeukocyBiol_2002_v71_p212.pdf	869629	no	11
			204f5a22c2b25cecb18ee2345180240906de2f82		
Warnings:					
Information:					
16	NPL Documents	Nakajima_et_al_Blood_2001_v98_p1127.pdf	162867	no	8
			9e0c2062f8a99a1e4d8cb1b458551a8dcafa6068		
Warnings:					
Information:					
17	NPL Documents	Nakajima_et_al_JAllClinImmunol_2004_v113_p528.pdf	799256	no	8
			0e99f5c257d8c862dff939513f263067af30256a		
Warnings:					
Information:					
18	NPL Documents	Oehler_et_al_Blood_2000_v95_p1086.pdf	99892	no	7
			f084170cac723ac7895c377f3ceb6fbbedb59f65c		
Warnings:					
Information:					
19	NPL Documents	Pucharcos_et_al_FEBS_Lett_2000_v478_p43.pdf	1042360	no	9
			0bd50e99179da30051ed493260c956a74bd93c73		
Warnings:					
Information:					
20	NPL Documents	Savage_ClinMedJRCPL_2002_v2_p458.pdf	218492	no	7
			5b298970da5375bb5f7006cc25e85e55fad89acc		
Warnings:					
Information:					
21	Foreign Reference	WO02033122.pdf	3483153	no	90
			137cdf1b24c8b653de037027325673039c855e5c		
Warnings:					
Information:					
22	Foreign Reference	WO02089829.pdf	3251346	no	64
			80151c06e350f0c94e3f500ad9b1dc6291c7ad05		
Warnings:					
Information:					
23	Foreign Reference	WO97039148.pdf	2452408	no	57
			28df1b69bc544fe430c23c65608b67f6f8f7ab59c		
Warnings:					

<b>Information:</b>					
24	NPL Documents	Bochner_JAllClinImmunol_2000_v106_S292.pdf	13817704 2a8f71013c4fa9f9525052eda7927363c2f31bf	no	11
<b>Warnings:</b>					
<b>Information:</b>					
25	NPL Documents	Nakajima_et_al_Blood_2002_v100_p3861.pdf	9417960 02fbc3c487fa51197bb5c377c017bf4ae941d34	no	8
<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	Nutku_et_al_Blood_2003_v101_p5014.pdf	8382031 ada38f62da32d17164a670c4ec80bd6e5933af37	no	7
<b>Warnings:</b>					
<b>Information:</b>					
27	NPL Documents	Pfaffl_NuclAcidRes_2001_v29_e45.pdf	5941406 18f097a44ec0efa2a8e54541ae2ba8d76aae688a	no	6
<b>Warnings:</b>					
<b>Information:</b>					
28	NPL Documents	Tajiri_et_al_Thyroid_1997_v7_p575.pdf	1714069 116af3edb4a40193fea57a657e4a4f7dedbcf2dc	no	4
<b>Warnings:</b>					
<b>Information:</b>					
29	NPL Documents	Hirai_et_al_Crit_Rev_Immunol_1997_v17_p325_pdf_part_1.pdf	20224745 d3eaf1f972a363e1323f0e3cf438136e229dc0930	no	15
<b>Warnings:</b>					
<b>Information:</b>					
30	NPL Documents	Hirai_et_al_Crit_Rev_Immunol_1997_v17_p325_pdf_part_2.pdf	19894448 fb8dfaf75b82148db7c8453c918d76d8e1362689	no	13
<b>Warnings:</b>					
<b>Information:</b>					
31	Fee Worksheet (PTO-875)	fee-info.pdf	32061 aea92009880e2508a6a2c8417c0e28ffeddd50e1	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			128719367		

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

**If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.**

**National Stage of an International Application under 35 U.S.C. 371**

**If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.**

**New International Application Filed with the USPTO as a Receiving Office**

**If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.**